# SK Biopharmaceuticals

AI-Driven Drug Discovery Reaches $2.5 Billion Milestone as Insilico and SK Biopharmaceuticals Ink Mega-Deal

Insilico Medicine and SK Biopharmaceuticals have entered into a $2.5 billion strategic partnership to develop AI-driven treatments for neuro-immune diseases. The deal highlights the pharmaceutical industry's aggressive pivot toward generative AI to streamline and accelerate the discovery of complex drug candidates.